Concepedia

Publication | Open Access

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

DOIFull Paper Access

182

Citations

40

References

2014

Year

David A. Reardon, Burt Nabors, Warren Mason, James Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, A. Cseh, Yan Fu,
Neuro-Oncology

Abstract

Afatinib has a manageable safety profile but limited single-agent activity in unselected recurrent GBM patients.

References

YearCitations

Page 1